TPST Tempest Therapeutics Inc
Price (delayed)
$0.7599
Market cap
$34.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$19.66M
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct
Highlights
Tempest Therapeutics's debt has decreased by 26% YoY and by 13% from the previous quarter
The EPS has grown by 21% YoY
The equity has soared by 67% from the previous quarter but it has contracted by 29% YoY
The quick ratio is down by 49% year-on-year but it is up by 35% since the previous quarter
The net income has contracted by 42% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of TPST
Market
Valuations
Earnings
Shares outstanding
45.48M
Market cap
$34.56M
Enterprise value
$19.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.03M
Net income
-$41.84M
EBIT
-$40.53M
EBITDA
-$38.83M
Free cash flow
-$33.46M
Per share
Balance sheet
Liquidity
EPS
-$1.5
EPS diluted
-$1.5
Free cash flow per share
-$1.2
Book value per share
$0.44
Revenue per share
$0
TBVPS
$1.49
Total assets
$41.49M
Total liabilities
$22.36M
Debt
$15.37M
Equity
$19.13M
Working capital
$17.25M
Debt to equity
0.8
Current ratio
2.21
Quick ratio
2.13
Net debt/EBITDA
0.38
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-103.4%
Return on equity
-245.6%
Return on invested capital
-244.4%
Return on capital employed
-148.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TPST stock price
How has the Tempest Therapeutics stock price performed over time
Intraday
6.34%
1 week
-5.15%
1 month
-6.12%
1 year
-85.07%
YTD
-8.94%
QTD
2.97%
Financial performance
How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.03M
Net income
-$41.84M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 44% YoY and by 18% QoQ
The net income has contracted by 42% YoY and by 18% from the previous quarter
Growth
What is Tempest Therapeutics's growth rate over time
Valuation
What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
1.73
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 21% YoY
The equity has soared by 67% from the previous quarter but it has contracted by 29% YoY
The price to book (P/B) is 46% lower than the last 4 quarters average of 3.0 and 4.1% lower than the 5-year quarterly average of 1.7
Efficiency
How efficient is Tempest Therapeutics business performance
TPST's return on invested capital has dropped by 128% year-on-year and by 39% since the previous quarter
The ROE has contracted by 31% from the previous quarter but it has grown by 13% YoY
The company's return on assets fell by 26% YoY and by 25% QoQ
Dividends
What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TPST.
Financial health
How did Tempest Therapeutics financials performed over time
The company's total assets is 86% higher than its total liabilities
The quick ratio is down by 49% year-on-year but it is up by 35% since the previous quarter
The current ratio has declined by 48% year-on-year but it is up by 31% since the previous quarter
Tempest Therapeutics's debt is 20% less than its equity
The equity has soared by 67% from the previous quarter but it has contracted by 29% YoY
The debt to equity has declined by 48% since the previous quarter but it is up by 3.9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.